medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-9-40-45medsovet-2474Research ArticleСПАСТИЧЕСКИЕ РАССТРОЙСТВАSPASTIC DISORDERSБотулинотерапия (incobotulinumtoxin А) в комплексной реабилитации подростков с детским церебральным параличом (клинические случаи)Botulinum toxin therapy (Incobotulinumtoxin А) in the complex rehabilitation of adolescents with cerebral palsy (clinical case)КостенкоЕ. В.KostenkoE. V.ПетроваЛ. В.PetrovaL. V.ГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России; ГАУЗ Московский научно-практический центр медицинской реабилитации, восстановительной и спортивной медициныРоссияPirogov Russian National Research Medical University, Moscow; Pirogow City Clinical Hospital; Moscow Centre for Research and Practice in Medical Rehabilitation, Restorative and Sports Medicine of Moscow Healthcare DepartmentRussian FederationГАУЗ Московский научно-практический центр медицинской реабилитации, восстановительной и спортивной медициныРоссияMoscow Centre for Research and Practice in Medical Rehabilitation, Restorative and Sports Medicine of Moscow Healthcare DepartmentRussian Federation201829052018094045Copyright © Костенко Е.В., Петрова Л.В., 20182018Костенко Е.В., Петрова Л.В.Kostenko E.V., Petrova L.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2474

В статье представлены клинические случаи пациентов с детским церебральным параличом (ДЦП) в подростковом возрасте. Показана возможность комплексной реабилитации с применением ботулинотерапии (инкоботулотоксин А, Ксеомин) для снижения спастичности, улучшения активных и пассивных движений. Применение инкоботулотоксина А (Ксеомина) показало значимый, стойкий, длительный эффект в отношении уменьшения спастичности, пассивной функции и функции ходьбы у пациентов подросткового возраста с ДЦП. Применение препарата в суммарной дозе от 7,8 до 9,1 ЕД/кг массы тела эффективно и безопасно.

The article presents clinical cases of patients with cerebral palsy (CP) in adolescence. The possibility of complex rehabilitation with the use of botulinum therapy (Xeomin) to reduce spasticity, improve active and passive movements is shown. Conclusion. The use of InkobotulinumtoxinА (Xeomin) has shown a significant, persistent, long-term effect on reducing spasticity, passive function and walking in adolescent patients with cerebral palsy. The use of the drug in the total dose of 7,8 to 9,1 U/kg body weight was effective and safe.

детский церебральный параличIncobotulinumtoxin Аксеоминреабилитацияспастичностьcerebral palsyIncobotulinumtoxinАxeominrehabilitationspasticityReferencesГузева В.И., Куренков А.Л., Змановкая В.А., Батышева Т.Т., Семенова К.А., Жеребцова В.А., Владыкина Л.Н., Попков Д.А. Детский церебральный паралич. В кн.: Федеральное руководство по детской неврологии. Под. ред. Гузевой В.И. М.: ООО «МК», 2016.Guzeva VI, Kurenkov AL, Zmanikovaya VA, Batysheva TT, Semenova KA, Zherebtsova VA, Vladykina LN, Popkov DA. Infantile cerebral palsy. In: Federal Guideline for Pediatric Neurology. Edited by Guzevoy VI. M.: MK LLC, 2016.Антипенко Е.А., Шулындин А.В., Густов АВ. Детский церебральный паралич у взрослых. Медицинский альманах, 2016, 5(45): 173-175.Antipenko EA, Shulyndin AV, Gustov AV. Cerebral palsy in adults. Meditsinsky Almanakh, 2016, 5 (45): 173-175.Шулындин А.В., Антипенко Е.А. Детский церебральный паралич у взрослых. Неврологический вестник, 2017, 3: 64-70.Shulyndin AV, Antipenko EA. Cerebral palsy in adults. Nevrologichesky Vestnik, 2017, 3: 64-70.Лечение спастичности у детей с церебральными параличами. Метод. рекомендации №15 под ред. Батышевой Т.Т.,М., 2011: 35.Treatment of spasticity in children with cerebral palsy. Method. Guidelines No. 15 Edited by Batysheva TT, Moscow, 2011: 35Тонконоженко Н.Л., Клиточенко Г.В., Кривоножкина П.С., Малюжинская Н.В. Детский церебральный паралич: клинические рекомендации по лечению и прогноз. Лекарственный вестник, 2015, 57, 9: 26-30.Tonkonozhenko NL, Klitochenko GV, Krivonozhkina PS, Malyuzhinskaya NV. Infantile cerebral palsy: clinical guidelines for treatment and prognosis. Lekarstvenny Vestnik, 2015, 57, 9: 26-30.Лобов М.А., Белоусова Е.Д., Шаховская Н.И., Малиновская О.Н. Ботокс ® в лечении детского церебрального паралича. Альманах клинической медицины, 2001, 4: 202-207.Lobov MA, Belousova ED, Shakhovskaya NI, Malinovskaya ON. Botox® in the treatment of infantile cerebral palsy. Almanac of Clinical Medicine, 2001, 4: 202-207.Куренков А.Л., Клочкова О.А., Бурсагова Б.И., Кузенкова Л.М., Каримова Х.М., Мамедьяров А.М., Артеменко А.Р., Петрова С.А. Применение препарата ботулинического токсина типа А (Ботокс) в лечении детского церебрального паралича. Нервно-мышечные болезни, 2014, 3: 28-40.Kurenkov AL, Klochkova OA, Bursagova BI, Kuzenkova LM, Karimova Kh.M., Mamedyarov AM, Artemenko AR, Petrova SA. The use of type a botulinum toxin (Botox) in the treatment of infantile cerebral palsy. Nervno-Myshechnye Bolezni, 2014, 3: 28-40.Куренков А.Л., Клочкова О.А., Бурсагова Б.И., Кузенкова Л.М., Артеменко А.Р., Фальковский И.В. Опыт применения препарата ботулинического токсина типа А (Onabotulinumtoxin A) в лечении пациентов с детским церебральным параличом. Медицинский совет, 2017, 1S: 37-43.Kurenkov AL, Klochkova OA, Bursagova BI, Kuzenkova LM, Artemenko AR, Falkovski IV. Experience in using type a botulinum toxin (Onabotulinumtoxin A) in the treatment of patients with infantile cerebral palsy. Meditsinsky Sovet, 2017, 1S: 37-43.Placzek R, Siebold D, Funk J. Development of Treatment Concepts for the Use of Botulinum Toxin A in Children with Cerebral Palsy. Toxins [Internet]. MDPI AG, 2010 Aug 27, 2(9): 2258–71. Available from: http: //dx.doi.org/10.3390/toxins2092258.Placzek R, Siebold D, Funk J. Development of Treatment Concepts for the Use of Botulinum Toxin A in Children with Cerebral Palsy. Toxins [Internet]. MDPI AG, 2010 Aug 27, 2(9): 2258–71. Available from: http: //dx.doi.org/10.3390/toxins2092258.Sprinz A, Dercks M, Weglage J, Nagel A. Treatment of cerebral palsy: Use of botulinum neurotoxin type A free of complexing proteins (Xeomin®) in childhood. Neuropediatrics [Internet]. Georg ThiemeVerlag KG, 2008 Dec, 39(05). Available from: http: //dx.doi.org/10.1055/s-0029-1215841.Sprinz A, Dercks M, Weglage J, Nagel A. Treatment of cerebral palsy: Use of botulinum neurotoxin type A free of complexing proteins (Xeomin®) in childhood. Neuropediatrics [Internet]. Georg ThiemeVerlag KG, 2008 Dec, 39(05). Available from: http: //dx.doi.org/10.1055/s-0029-1215841.Sprinz A, Nagel A. Multimodal treatment of Cerebral Palsy (CP) including physical therapy, Botulinumtoxin und Lokomat-Training: A case report. Neuropediatrics [Internet]. Georg ThiemeVerlag KG, 2008 Dec, 39(05). Available from: http: //dx.doi. org/10.1055/s-0029-1215842.Sprinz A, Nagel A. Multimodal treatment of Cerebral Palsy (CP) including physical therapy, Botulinumtoxin und Lokomat-Training: A case report. Neuropediatrics [Internet]. Georg ThiemeVerlag KG, 2008 Dec, 39(05). Available from: http: //dx.doi. org/10.1055/s-0029-1215842.Berweck S, Schröder S, Huß K, Borggraefe I, Heinen F. Safety of botulinum toxin treatment in children with cerebral palsy in correlation to GMFCS level. Neuropediatrics [Internet]. Georg ThiemeVerlag KG, 2008 Dec, 39(05). Available from: http: //dx.doi.org/10.1055/s-0029-1215840.Berweck S, Schröder S, Huß K, Borggraefe I, Heinen F. Safety of botulinum toxin treatment in children with cerebral palsy in correlation to GMFCS level. Neuropediatrics [Internet]. Georg ThiemeVerlag KG, 2008 Dec, 39(05). Available from: http: //dx.doi.org/10.1055/s-0029-1215840.Hesse S, Mach H, Fröhlich S, Behrend S, Werner C, Melzer I. An early botulinum toxin A treatment in subacute stroke patients may prevent a disabling finger flexor stiffness six months later: a randomized controlled trial. ClinRehabil, 2012, 26(3): 237-245.https: //doi. org/10.1177/0269215511421355.Hesse S, Mach H, Fröhlich S, Behrend S, Werner C, Melzer I. An early botulinum toxin A treatment in subacute stroke patients may prevent a disabling finger flexor stiffness six months later: a randomized controlled trial. ClinRehabil, 2012, 26(3): 237-245.https: //doi. org/10.1177/0269215511421355.Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, Armstrong MJ, Gloss D, Potrebic S, Jankovic J, Karp BP, Naumann M, So YT, Yablon SA. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016, 86(19): 1818-1826. https: //doi.org/10.1212/WNL.0000000000002560.Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, Armstrong MJ, Gloss D, Potrebic S, Jankovic J, Karp BP, Naumann M, So YT, Yablon SA. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016, 86(19): 1818-1826. https: //doi.org/10.1212/WNL.0000000000002560.Wissel J, Bensmail D, Ferreira JJ, Molteni F, Satkunam L, Moraleda S, Rekand T, McGuire J, Scheschonka A, Flatau-Baqué B, Simon O, Rochford ET, Dressler D, Simpson DM, TOWER study investigators. Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study. Neurology, 2017, 88(14): 1321-1328. https: //doi.org/10.1212/WNL.0000000000003789Wissel J, Bensmail D, Ferreira JJ, Molteni F, Satkunam L, Moraleda S, Rekand T, McGuire J, Scheschonka A, Flatau-Baqué B, Simon O, Rochford ET, Dressler D, Simpson DM, TOWER study investigators. Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study. Neurology, 2017, 88(14): 1321-1328. https: //doi.org/10.1212/WNL.0000000000003789Carraro E, Trevisi E, Martinuzzi A. Safety profile of incobotulinum toxin A (Xeomin) in gastrocnemious muscles injections in children with cerebral palsy: Randomized double-blind clinical trial. Eur J Paediatr Neurol, 2016, 20(4): 532537. https: //doi.org/10.1016/j.ejpn.2016.04.008.Carraro E, Trevisi E, Martinuzzi A. Safety profile of incobotulinum toxin A (Xeomin) in gastrocnemious muscles injections in children with cerebral palsy: Randomized double-blind clinical trial. Eur J Paediatr Neurol, 2016, 20(4): 532537. https: //doi.org/10.1016/j.ejpn.2016.04.008.Hijazi S, Arcas M. Effectiveness and safety assessment of incobotulinumtoxina (Xeomin) injections in the lower-limb muscles of young, low-weight children with cerebral palsy. Toxicon, 2016, 123: 39.Hijazi S, Arcas M. Effectiveness and safety assessment of incobotulinumtoxina (Xeomin) injections in the lower-limb muscles of young, low-weight children with cerebral palsy. Toxicon, 2016, 123: 39.Leon-Valenzuela A, Sanchez Palacios J, del PinoAlgarrada R. Clinical practice with incobotulinumtoxina (Xeomin) in the treatment of spasticity in children with cerebral palsy. Toxicon, 2016, 123: 53.Leon-Valenzuela A, Sanchez Palacios J, del PinoAlgarrada R. Clinical practice with incobotulinumtoxina (Xeomin) in the treatment of spasticity in children with cerebral palsy. Toxicon, 2016, 123: 53.Delgado M, Hirtz D, Aisen M et al. Practice Parameter: Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology, 2010, 74(4): 336-34.Delgado M, Hirtz D, Aisen M et al. Practice Parameter: Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology, 2010, 74(4): 336-34.

The authors declare that there are no conflicts of interest present.